常见儿科病原体对LY163892的体外敏感性
In vitro susceptibilities of common pediatric pathogens to LY163892.
作者信息
Shelton S, Nelson J D
机构信息
Department of Pediatrics, University of Texas Health Science Center, Dallas 75235.
出版信息
Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.
Abstract
LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid. It has greater stability than cefaclor and greater activity against beta-lactamase-producing Haemophilus influenzae and Escherichia coli. LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens.
摘要
LY163892是一种口服碳头孢烯类抗生素，其抗菌谱与头孢克洛和阿莫西林-克拉维酸相似。它比头孢克洛具有更高的稳定性，对产β-内酰胺酶的流感嗜血杆菌和大肠杆菌具有更强的活性。LY163892对链球菌的活性低于阿莫西林，对卡他莫拉菌的活性低于阿莫西林-克拉维酸，但对其他病原体的活性相当。
相似文献
1
In vitro susceptibilities of common pediatric pathogens to LY163892.
Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.
2
Comparative in-vitro activity of a new oral carbacephem, LY163892.
J Antimicrob Chemother. 1988 Oct;22(4):445-56. doi: 10.1093/jac/22.4.445.
3
In vitro activity of BAY v 3522, a new oral cephalosporin.
Antimicrob Agents Chemother. 1990 Sep;34(9):1855-7. doi: 10.1128/AAC.34.9.1855.
4
In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.
Antimicrob Agents Chemother. 1991 Jul;35(7):1504-7. doi: 10.1128/AAC.35.7.1504.
5
In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
J Chemother. 1996 Jun;8(3):193-9. doi: 10.1179/joc.1996.8.3.193.
6
In-vitro activity and beta-lactamase stability of LY163892.
J Antimicrob Chemother. 1988 Aug;22(2):155-65. doi: 10.1093/jac/22.2.155.
7
Global surveillance of bacterial susceptibility to cefaclor: 1988-1990.
Clin Ther. 1993 Jan-Feb;15(1):88-96.
8
[Serotype distribution and drug resistance of , and isolated from nasopharynx of Uygur children].
Zhonghua Er Ke Za Zhi. 2018 Apr 2;56(4):279-283. doi: 10.3760/cma.j.issn.0578-1310.2018.04.008.
9
In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.
10
Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
Chemotherapy. 1992;38(1):28-35. doi: 10.1159/000238939.
引用本文的文献
1
The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.
Front Microbiol. 2022 Mar 24;13:807955. doi: 10.3389/fmicb.2022.807955. eCollection 2022.
2
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs. 1993 May;45(5):716-36. doi: 10.2165/00003495-199345050-00008.
3
Pharmacokinetics of LY163892 in infants and children.
Antimicrob Agents Chemother. 1988 Nov;32(11):1738-9. doi: 10.1128/AAC.32.11.1738.
4
Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.
Antimicrob Agents Chemother. 1988 Oct;32(10):1477-80. doi: 10.1128/AAC.32.10.1477.
5
Loracarbef concentrations in middle ear fluid.
Antimicrob Agents Chemother. 1990 Oct;34(10):2030-1. doi: 10.1128/AAC.34.10.2030.
6
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.
Antimicrob Agents Chemother. 1991 May;35(5):967-71. doi: 10.1128/AAC.35.5.967.
7
Pharmacokinetics of loracarbef in pediatric patients.
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):201-4. doi: 10.1007/BF03190146.
8
Pharmacokinetics of loracarbef and interaction with acetylcysteine.
Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):851-5. doi: 10.1007/BF01960891.
9
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.
Infection. 1992 May-Jun;20(3):176-82. doi: 10.1007/BF01704619.
10
Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.
Infection. 1992 Sep-Oct;20(5):301-8. doi: 10.1007/BF01710806.
Zotero 插件